Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 6.86
+0.10 (1.48%)
At close: Sep 30, 2026
Abera Bioscience AB Market Cap
Abera Bioscience AB has a market cap or net worth of 140.62 million as of October 9, 2026. It is the 39,563rd most valuable company in the world and the 555th biggest in Sweden. Its market cap has increased by 36.71% in one year.
Market Cap
140.62M
Enterprise Value
122.91M
Revenue
9.10M
Global Rank
Country Rank
#555 Sweden
PE Ratio
n/a
ChartMarket Cap Chart
Since February 24, 2021, Abera Bioscience AB's market cap has increased from 115.59M to 140.62M, an increase of 21.66%. That is a compound annual growth rate of 3.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 140.62M | 12.10% |
| Dec 30, 2025 | 125.44M | 81.17% |
| Dec 30, 2024 | 69.24M | -7.23% |
| Dec 29, 2023 | 74.63M | 20.46% |
| Dec 30, 2022 | 61.96M | -64.21% |
| Dec 30, 2021 | 173.12M | 49.77% |
| Feb 24, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Elicera Therapeutics AB | 183.86M |
| Xintela AB | 154.60M |
| Diamyd Medical AB | 151.88M |
| Simris Group AB (PUBL) | 150.50M |
| NextCell Pharma AB | 127.91M |
| Initiator Pharma | 123.22M |
| OncoZenge AB | 115.37M |
| Ascelia Pharma AB | 114.84M |